• Home
• News
• About Us
• Contact

Patriot Act raised cost of anthrax research, study says
by Rita Uplend on May 12, 2010

While the Patriot Act and Bioterrorism Preparedness Act made it more difficult for anyone to obtain pathogens needed to launch a bioterror attack, the acts also had a few unintentional drawbacks, according to a study released this week in the Proceedings

Texas A&M urges greater involvement in biotech
by Nick Rees on March 25, 2010

College Station, Texas, is fast becoming an integral part of the nation's rapid response for pandemic threats and a prime location for turning lab discoveries into marketable products.

Negotiations to monitor Colorado chemical weapons hits impasse
by Ted Purlain on March 17, 2010

An impasse in negotiations on monitoring chemical weapons stored outside Pueblo, Colorado, between Colorado and Army officials has stalled plans to blow up thousands of shells containing mustard agent.

Emergent BioSolutions Inc. CEO named outstanding international business leader
by Nick Rees on March 12, 2010

Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc., has been named as one of Maryland's outstanding international business leaders by the World Trade Center Institute.

David Southwell named executive V.P. and CFO of Human Genome Sciences
by Nick Rees on March 10, 2010

David P. Southwell has been named executive vice president and chief financial officer of Human Genome Sciences, Inc.

Mich. police chief joins Emergent BioSolutions Inc.
by Ted Purlain on February 24, 2010

Lansing, Michigan police chief Mark Alley has announced that he will retire within the month to take a new position at Emergent BioSolutions Inc. as the company's senior director of risk management.

Autonomous biothreat sensors to be developed
by Nick Rees on February 10, 2010

Qinetiq North America is working in conjunction with Brewer Science and Applied Systems Intelligence on a program to develop an autonomous, self-deploying sensor to serve as a roving, early-warning detector of biological warfare activity.

Darpa to develop immortal organisms
by Daniel Purt on February 10, 2010

Darpa, in a move that means to use bioweapons for good, has announced the investment of $6 million into a project that will create "synthetic organisms" that never die but can be killed with the flick of a molecular switch.

Effort extended in fight against Lassa virus
by Nick Rees on February 10, 2010

A major extension in the collaborative effort between Corgenix Medical Corporation and Tulane University has been announced to combat viral hemorrhagic fever.

Construction on GenPhar's S.C. headquarters halted
by Nick Rees on February 8, 2010

Construction on GenPhar's new 50,000-square-foot, $33 million Mount Pleasant, South Carolina headquarters has been put on hold after the town ordered work to halt.

New virtual community to connect bioterrorism experts
by Tina Redlup on February 2, 2010

The Delaney Center at Mount St. Mary's University has launched a new virtual community that allows intelligence officers, students and even Capitol Hill executives to network with bioterrorism experts, bodyguards and academics

University of Florida dedicates new headquarters for Emerging Pathogens Institute
by Tina Redlup on January 27, 2010

The University of Florida has held a ribbon cutting ceremony for its new, 80,000-square-foot Emerging Pathogens Institute.

Report finds OSU president acted within his authority in ending anthrax study
by Nick Rees on January 21, 2010

An Oklahoma State University faculty report has declared that university president Burns Hargis was acting within his authority when he stopped a research project on anthrax vaccines that would have euthanized baboons.

Maryland approves plan for state public health lab
by Rita Uplend on January 21, 2010

A $6.45 million plan for design work for a planned state public health laboratory at East Baltimore Development, Inc.'s massive biotechnology research park has been approved by the Maryland Board of Public Works.

Biodefense industry leaders meet to discuss changes to BioShield
by Rita Uplend on January 14, 2010

Biodefense industry leaders have met to discuss how to facilitate the development and approval of products in the biodefense sector following the decision to remove funds from the BioShield Special Reserve Fund.

Select Agents and Toxins list hindering biosecurity, scientists say
by Nick Rees on January 12, 2010

Scientists have said that the Select Agents and Toxins list, rather than strengthening security, is, in fact, undermining the nation's security.

Subject: BPW - R. Don Elsey joins MdBio Foundation's board of directors
by Ted Purlain on January 12, 2010

Emergent BioSolutions Inc.'s R. Don Elsey, chief financial officer and senior vice president of finance and administration, has joined the MdBio Foundation's board of directors.

Researcher discovers how anthrax attacks cells
by Daniel Purt on January 5, 2010

An international research scholar at Howard Hughes Medical Institute has, for the first time, identified the cell signaling event that sets anthrax's attack on the human body in motion.

University of Texas Biocontainment Training Center receives federal funding
by Nick Rees on December 30, 2009

The National Biocontainment Training Center at the University of Texas has received $5 million in federal funding support.

Study published by Soligenix on characteristics of ricin A chain
by Nick Rees on December 29, 2009

Soligenix, Inc., has announced the publication of an article that details the characteristics of several immunodominant regions of ricin A chain - the antigenic component of Rivax - in the January 2010 edition of Infection and Immunity.

Second anthrax death in Glasgow, more cases being investigated
by Tina Redlup on December 24, 2009

A second Glasgow heroin user has died from an anthrax infection, health officials have confirmed.

Researchers discover how smallpox kills
by Nick Rees on December 24, 2009

While smallpox has been eradicated from the planet as a naturally occurring virus, it still remains a high level biothreat.

OctaFlex gets grant to develop bioweapon wash
by Nick Rees on December 24, 2009

Following the recent passing by Congress of the Fiscal Year 2010 Defense Appropriations Bill, private sector projects in western South Dakota stand to receive over $14 million in new defense appropriations, some of which will be used to fight bioterror.

UIC given no to open new biolab
by Daniel Purt on December 24, 2009

The University of Chicago Medical Center has been notified by the United States Department of Energy that it has full approval to commence operations at its new Howard T. Ricketts Laboratory.

Oklahoma Representative reacts to cancellation of anthrax study
by Nick Rees on December 23, 2009

Phil Richardson, an Oklahoma State Representative, veterinarian and farmer, has taken aim at Oklahoma State University for its recent cancellation of an anthrax study that would have required testing and euthanasia on primates.

DoD bill will fund biological attack sensors
by Nick Rees on December 21, 2009

Under the recently $636 billion Department of Defense appropriations bill passed by the Senate, Michigan companies will soon see grants to aid in the prevention of bioterrorism.

Pennsylvania hospitals given grant to fight bioterror and pandemics
by Tina Redlup on December 21, 2009

Jameson and Ellwood City hospitals in Pennsylvania will receive a $1.6 million grant award to aid them in their fight against bioterrorism and pandemics.

Emergent BioSolutions reacts to BARDA's Request for Proposal cancellation
by Nick Rees on December 9, 2009

The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA's Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office's Broad Agency Announcement.

UIC given funds to develop new bioweapon antibiotics
by Nick Rees on December 4, 2009

Four million dollars in stimulus package funds will be given to researchers at the University of Illinois at Chicago to aid in the development of new antibiotics to treat anthrax, tularemia and plague.

Medizone International announces positive sporicidal test results for its AsepticSure technology
by Nick Rees on December 3, 2009

Medizone International, Inc., has announced that its proprietary AsepticSure technology has continuously broken decontamination barriers in tests, establishing it as an extremely potent sporicidal technology.

Anthrax vaccine project stopped over animal rights
by Nick Rees on November 30, 2009

Oklahoma State University has put a stop to a project meant to test anthrax vaccines and treatment on baboons.

Cowpox's genetic code could lead to bioweapon vaccines
by Tina Redlup on November 25, 2009

Research into deciphering the cowpox virus' genetic coding has revealed the potential to treat other diseases, including those that pose a biothreat such as ebola.

Export of bioweapon technology to India to remain restricted
by Paul Tinder on November 24, 2009

The United States has maintained restrictions on the export of as many as 11 of its 16 dual use technology regimes to India, including on dual use technology in chemical and biological weapons.

Consortium formed to create thermostable ricin vaccine
by Nick Rees on November 23, 2009

Soligenix, Inc., a late-stage biotechnology company, has announced that is has formed a consortium to aid in developing thermostable technology to advance RiVax and other rapidly acting vaccines.

Positive results reported for fight against VHF
by Nick Rees on November 20, 2009

Peregrine Pharmaceuticals, Inc., has announced that its researchers have presented positive data on progress as part of its federally funded preclinical viral hemorrhagic fever program.

Anthrax drug maker questions approval process for drug
by Paul Tinder on November 19, 2009

The delay to Human Genome Sciences' experimental anthrax drug appears inconsistent with published final rules governing the development of new drugs by the FDA, an HGS spokesperson has said.

James Neal joins XOMA Ltd., to aid in building biodefense programs
by Nick Rees on November 18, 2009

James R. Neal has joined XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, as vice president of business development.

Maryland biopharmaceutical company purchases East Baltimore bioscience center
by Pat Dulnier on November 17, 2009

A Rockville, Maryland based biopharmaceutical company has purchased the East Baltimore bioscience nonprofit MdBio Foundation's 55,000-square-foot BioProcessing Center in East Baltimore.

Experimental anthrax treatment denied approval
by Nick Rees on November 17, 2009

U.S. health regulators have decline to approve a new experimental treatment for anthrax infection from Human Genome Sciences, Inc.

Congressional commission says threat of bioterrorism not being addressed
by Nick Rees on November 16, 2009

An interim report by the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism states that the United States has failed to address the threat of bioterrorism.

New bioterror response research institute opens near Washington, D.C.
by Paul Tinder on November 16, 2009

The Stanford Research Institute International's new research facility in Harrisonburg, Va., has officially opened after four years of planning and construction.

Boston biodefense complex faces legal challenges
by Ted Purlain on November 16, 2009

A $198 million Boston University Medical Center biological defense laboratory complex's opening has been blocked by federal and state lawsuits brought by the public.

Emergent BioSolutions acquires manufacturing facility from MdBio
by Pat Dulnier on November 13, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. has completed the acquisition of a 55,000-square-foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the city of Baltimore.

SRI International opens research center in Virginia
by Ted Purlain on November 12, 2009

RI International opened a new facility for its Center for Advanced Drug Research, where scientists will work on developing vaccines, more quickly diagnosing infections and developing new treatments.

Scientists Announce Possible Treatment for Deadly Virus
by Pat Dulnier on November 11, 2009

A team of Australian and U.S. scientists believe they have found an antibody that could protect humans from the deadly Hendra virus, Australia's Northern Miner reported yesterday.

The zombies are fictional; the science is real
by Daniel Purt on October 30, 2009

At first glance, fictional zombies, real diseases and mathematics do not seem to have very much in common, but Dr. Robert Smith? [sic] is putting all these elements to use in creating mathematical models for infectious diseases.

Michigan Security Network boosts state’s economy
by Mary J. Lewis on October 27, 2009

Fighting Michigan’s well-documented economic struggles, industry leaders are looking for innovation that will help jumpstart the econo

Emergent BioSolutions CEO named Ernst & Young Entrepreneur of the Year
by Ted Purlain on June 18, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced June 18, 2009, that Fuad El-Hibri, its chairman and CEO, received the Ernst & Young Entrepreneur of the Year 2009 Award in the Technology category in Greater Washington.

Emergent BioSolutions submits its plan for vaccine contract to FDA
by Pat Dulnier on May 13, 2009

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced May 13, 2009, that it has submitted to the U.S. Food and Drug Administration a development plan for the company’s recombinant protective antigen anthrax vaccine candidate.

Search

Subscribe to our newsletter

RSS Feed